Korsana Biosciences, Inc. carries no debt; cash flow comfortably covers obligations.

Korsana Biosciences, Inc. has insufficient data to evaluate this check.

Korsana Biosciences, Inc. has insufficient data to evaluate this check.

Korsana Biosciences, Inc. has insufficient data to evaluate this check.

Korsana Biosciences, Inc. has a net cash position, so leverage is healthy.

Korsana Biosciences, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Korsana Biosciences, Inc.'s profit margin has decreased (130.95%) in the last year from -152.85% to -353.00%, signaling decreasing performance

Korsana Biosciences, Inc. has insufficient data to evaluate this check.

Korsana Biosciences, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Korsana Biosciences, Inc.'s return on equity of -87.96%, is lower than 15.00%, indicating bad performance

Korsana Biosciences, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Korsana Biosciences, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Korsana Biosciences, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Korsana Biosciences, Inc. has a free cash flow yield of 0.00%, which is below the 2.00% threshold, indicating limited cash return relative to market value

Korsana Biosciences, Inc.'s yearly earnings has decreased 15.41% since last year from $-3.06M to $-3.53M, signaling decreasing performance

Korsana Biosciences, Inc. has insufficient data to evaluate this check.

ROIC -134.15% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Korsana Biosciences, Inc.'s 3-year revenue CAGR of 91.14% is positive, indicating growing revenue over the past 3 years

Korsana Biosciences, Inc. had revenue growth in 3 out of 5 years, indicating consistent revenue performance

Korsana Biosciences, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Korsana Biosciences, Inc. has insufficient data to evaluate this check.

Korsana Biosciences, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Korsana Biosciences, Inc. has insufficient data to evaluate this check.

Korsana Biosciences, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Korsana Biosciences, Inc. has insufficient data to evaluate this check.

Korsana Biosciences, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Korsana Biosciences, Inc. has a price-to-book ratio of 3.81x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Korsana Biosciences, Inc. has a price-to-sales ratio of 10.20x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue